HCA Healthcare hospital in Richmond, VA temporarily halts NICU admissions after unexplainable fractures found in three babies. Investigation underway.

In a glimpse at the future of medical training, students in Gainesville-based University of Florida's College of Nursing are learning to collaborate with colleagues and communicate with patients ...

Barclay Berdan became CEO of Arlington-based Texas Health Resources in 2014 and over the last decade has built a strong culture with an eye toward growth.

Discover how women in healthcare leadership roles drove significant improvements in their organizations through mindset shifts, transparency, and prioritizing ...

Physicians say the pending closure of Dallas-based Steward Health Care's Sharon (Pa.) Regional Hospital has strained care coordination for patients seeking care at the facility, according to a Dec. 24 ...

BradenHealth acquires Perry Community Hospital in Tennessee, plans to rebuild and restore services. Learn more about the acquisition and BradenHealth's plans f ...

Here are six takeaways from the letter: Cleveland Clinic Florida's hospital-at-home program has treated more than 2,800 patients, for conditions including heart failure, pneumonia and kidney ...

Here are four hospital and health system CFO moves that Becker's has reported on since Dec. 23: 1. Rob Wood was promoted to CFO of Somers Point, N.J.-based Shore Medical Center. 2. Orlando Health St.

Philip Hall, a 48-year-old pharmacist of Jamestown, Tenn., has been arrested and charged with six counts of aggravated identity theft and nine counts of healthcare fraud. Mr. Hall owned and operated ...

Doug Boysen, president and CEO of Corvallis, Ore.-based Samaritan Health Services, plans to step down from the role in 2025. Mr. Boysen is working with the board to create a CEO transition plan, ...

Shore Medical Center in Somers Point, N.J., appointed two new executives Dec. 26. Rob Wood was promoted to CFO after spending 37 years with the system. He previously served as director of finance and ...

Zealand Pharma's GLP-2 drug candidate fails to gain FDA approval due to request for additional trial to confirm efficacy and safety.